1040P - Dalteparin vs. vitamin K antagonist (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency:...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Bioethics, Legal, and Economic Issues
Presenter Lesley Shane
Citation Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377
Authors L. Shane1, G. Dranitsaris2, S. Woodruff3, J. Galanaud4, G. Stemer5, P. Debourdeau6, B. Valtier7, L. Burgers8
  • 1Global Health And Value, Pfizer Inc., 10017-5755 - New York/US
  • 2Outcomes Research, Augmentium Pharma Consulting Inc, m4k 1n2 - Toronto/CA
  • 3Medical, Pfizer Inc., 10017-5755 - New York/US
  • 4Department Of Internal Medicine, Montpellier University Hospital, Montpellier/FR
  • 5Pharmacy, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna/AT
  • 6Oncology, Hopital Desgenettes, Lyon/FR
  • 7Medical, Pfizer France, 10017-5755 - Paris/FR
  • 8Public Affairs And Policy, Pfizer BV, Capelle a/d Ijssel/NL



In a randomized trial (i.e. CLOT) which evaluated extended duration prophylaxis of recurrent VTE in cancer patients (Lee et al, 2003), dalteparin reduced the relative risk of recurrent VTE by 52% compared to oral VKA therapy (P = 0.002). A recent subgroup analysis in patients with moderate to severe renal impairment at randomization also revealed lower absolute VTE rates with dalteparin (3% vs. 17%; p = 0.011). A patient level pharmacoeconomic analysis was conducted to evaluate these indications from the French, Austrian and Dutch health care system perspectives.


Resource utilization data contained within the database was extracted and converted into direct cost estimates for each country. Univariate analysis was used to compare the total cost of therapy between patients randomized to dalteparin or VKA therapy for each country. To estimate the cost per quality adjusted life year (QALY) gained with dalteparin, health state utilities were measured in 24 members of the general public using the Time Trade-Off technique.


When all of the cost components were combined for the entire population (n = 676), the dalteparin group had significantly higher mean overall costs than the VKA group in each of the respective countries (Table). However, the preference assessment revealed that 21 of 24 respondents (88%) selected dalteparin over VKA with an associated gain of 0.14 (95%CI: 0.10 – 0.18) QALYs, resulting in favourable cost effectiveness ratios.

Country* Dalteparin VKA Cost / QALY
France €2,267 (80) €1,352 (94) €6,600
Austria €2,687 (81) €2,012 (102) €4,900
Netherlands €2,376 (81) €1,724 (102) €4,697



Extended duration prophylaxis with dalteparin is a clinically and cost effective alternative to VKA for the prevention of recurrent VTEs in patients with cancer, especially in those with renal impairment.

Clinical trial identification

Legal entity responsible for the study

Pfizer Inc


Pfizer Inc


L. Shane: Employed by the sponsor; Pfizer Inc. G. Dranitsaris: Consultant to Pfizer Inc. S. Woodruff, B. Valtier, L. Burgers: Employed by Pfizer Inc. All other authors have declared no conflicts of interest.